Abbott Q2 FY26 GAAP EPS drops to $0.53; net sales rise 13% to $12.59 billion
ABT•Abbott reports second-quarter results
Abbott posted 2Q26 net earnings of $928 million, down 47.8%, with diluted EPS of $0.53 versus $1.31 adjusted.
Net sales climbed 13% to $12.59 billion, while comparable sales growth was 4.8%.
Operating earnings fell 17.5% to $1.69 billion as operating costs and expenses rose 19.9% to $10.9 billion.
Full-year guidance and pipeline updates
Full-year adjusted diluted EPS guidance was raised to $5.45-$5.60; comparable sales growth outlook was reaffirmed at 6.5%-7.5%.
Management flagged accelerating momentum into 2H. Abbott also said CE Mark was secured for Libre Duo, the FDA filing was completed for Amulet 360, and TECTONIC IVL U.S. trial enrollment finished.
